Weight Loss Drug Zepbound Cuts Heart Failure Risk

Published on August 1, 2024

Trial results show Eli Lilly’s weight loss drug Zepbound reduces the risk of hospitalization, death and other outcomes for obese adults with a common type of heart failure, the company said on Thursday as it continues to build a case for the medication’s wider health…

Read Full Article (External Site)